Acute treatment of migraine. Breaking the paradigm of monotherapy

BMC Neurology

Volumn 4, Issue , 2004, Pages

  Krymchantowski, Abouch Valenty ^a,b,c  

^a FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^b Instituto de Neurologia Deolindo Couto   (Brazil)

^c Headache Center of Rio   (Brazil)

Author keywords

Acute treatment; Changing approach; Migraine; Polytherapy

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; CAFFEINE; DIHYDROERGOTAMINE; DOMPERIDONE; DOPAMINE RECEPTOR BLOCKING AGENT; ERGOT DERIVATIVE; ERGOTAMINE; ERGOTAMINE DERIVATIVE; INDOMETACIN; METOCLOPRAMIDE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; PLACEBO; PROCHLORPERAZINE; RIZATRIPTAN; ROFECOXIB; SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST; SEROTONIN AGONIST; SUMATRIPTAN; TOLFENAMIC ACID; TRIMEBUTINE;

ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG RESPONSE; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; MIGRAINE; MONOTHERAPY; RECURRENT DISEASE; SIDE EFFECT;

ACUTE DISEASE; ANALGESICS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOPAMINE ANTAGONISTS; DRUG THERAPY, COMBINATION; GASTROINTESTINAL AGENTS; HUMANS; MIGRAINE DISORDERS; RECURRENCE; SEROTONIN RECEPTOR AGONISTS; TREATMENT OUTCOME;

EID: 2642543422     PISSN: 14712377     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2377-4-4     Document Type: Article

References (42)

1. Stewart WF, Schechter A, Lipton RB: Migraine heterogeneity, disability, pain intensity and attack frequency and duration. Neurology 1994, 44(suppl 4):S24-S39.
2. Rasmussen BK: Epidemiology of headache. Cephalalgia 1995, 15:45-68.
3. Headache Classification Committee of the International Headache Society: Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988, 8(suppl 7):1-96.
4. Stewart WF, Lipton RB, Simon D: Work-related disability: results from the American migraine study. Cephalalgia 1996, 16:231-238.
5. Lipton RB, Stewart WF: Prevalence and impact of migraine. Neurol Clin 1997, 15:1-13.
6. Ferrari MD, Haan J: Drug treatment of migraine attacks. In: Headache. Blue Books of Practical Neurology Edited by: Goadsby P, Silberstein SD. Newton:Butterworth-Heinemann; 1997:117-130.
7. Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF: Migraine diagnosis and treatment: results from the American Migraine Study II. Headache 2001, 41:638-645.
8. Dodick DW: Acute and prophylactic management of migraine. Clin Cornerstone 2001, 4:36-52.
9. Tfelt-Hansen P, Lipton RB: Prioritizing treatment. In: The Headaches Edited by: Olesen J, Tfelt-Hansen P, Welch KMA. New York:Raven Press; 1993:359-362.
10. Goadsby PJ, Lipton RB, Ferrari MD: Migraine - Current understanding and treatment. N Engl J Med 2002, 346:257-270.
11. Lipton RB, Stewart WF, Cady R, Hall C, O'Quinn S, Khun T, Gutterman D: 2000 Wolff Award. Sumatriptan for the range of headaches in migraine sufferers: results of the Spectrum Study. Headache 2000, 40:783-791.
12. Lipton RB, Hamelsky SW, Dayno JM: What do patients with migraine want from acute migraine treatment? Headache 2002, 42(suppl 1):3-9.
13. Saxena P, Tfelt-Hansen P: Triptans, 5-HT1B/1D Receptor Agonists in the acute treatment of Migraine. In: The Headaches Secondth edition. Edited by: Olesen J, Tfelt-Hansen P, Welch KMA. Philadelphia:Lippincott Williams & Wilkins; 2000:411-438.
14. Peroutka SJ: Beyond Monotherapy: Rational polytherapy in migraine. Headache 1998, 38:18-22.
15. Bates D, Ashford E, Dawson R, Ensink FB, Gilhus NE, Olesen J, Pilgrim AJ, Shevlin P: Subcutaneous sumatriptan during the migraine aura. Neurology 1994, 44:1587-1592.
16. Visser WH, de Vriend RH, Jaspers NHWM, Ferrari MD: Sumatriptan - nonresponders: a survey in 366 migraine patients. Headache 1996, 36:471-475.
17. Dahlof CG: How does sumatriptan perform in clinical practice? Cephalalgia 1995, 15(suppl 15):21-28.
18. Visser WH, de Vriend RH, Jaspers NHWM, Ferraria MD: Sumatriptan in clinical practice: a 2-year review of 453 migraine patients. Neurology 1996, 47:46-51.
19. International Headache Society Clinical Trials Subcommittee: Guidelines for controlled trials of drugs in migraine: second edition. International Headache Society. Members Handbook 2002:113-198.
20. Saxena P, Tfelt-Hansen P: Triptans, 5-HT1B/1D Receptor Agonists in the acute treatment of Migraine. In: The Headaches Secondth edition. Edited by: Olesen J, Tfelt-Hansen P, Welch KMA. Philadelphia:Lippincott Williams & Wilkins; 2000:411-438.
21. Dahlof C: Placebo-controlled clinical trials with ergotamine in the acute treatment of migraine. Cephalalgia 1993, 13:166-171.
22. Wyss PA, Rosenthaler J, Nuesch E, Aellig WH: Pharmacokinetic investigation of oral and IV dihydroergotamine in healthy subjects. Eur J Clin Pharmacol 1991, 41:597-602.
23. Tfelt-Hansen P, Saxena P: Ergot alkaloids in the acute treatment of migraine. In: The Headaches Secondth edition. Edited by: Olesen J, Tfelt-Hansen P, Welch KMA. Philadelphia:Lippincott Williams & Wilkins; 2000:399-409.
24. Tfelt-Hansen P, McEwen J: Nonsteroidal Anti-inflammatory Drugs in the Acute Treatment of Migraine. In: The Headaches Secondth edition. Edited by: Olesen J, Tfelt-Hansen P, Welch KMA. Philadelphia: Lippincott Williams & Wilkins; 2000:391-397.
25. Ferrari MD, James MH, Bates D, Pilgrim AJ, Ashford E, Anderson BA, Nappi G: Oral sumatriptan: possible benefit of a second dose, and incidence and treatment of headache recurrences. Cephalalgia 1994, 14:330-8.
26. Krymchantowski AV, Barbosa JS: Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study. Cephalalgia 2002, 22:309-312.
27. Burstein R: Deconstructing migraine headache into peripheral and central sensitization. Pain 2001, 89(2-3):107-110.
28. Ferrari MD: Systemic biochemistry. In: The Headaches Edited by: Olesen J, Tfelt-Hansen P, Welch KMA. New York:Raven Press; 1993:179-183.
29. Ebersberger A, Averbeck B, Messlinger K, Reeh PW: Release of substance P, calcitonin gene-related peptide and prostaglandin E2 from rat dura mater encephali following electrical and chemical stimulation in vitro. Neuroscience 1999, 89:901-907.
30. Moskowitz MA, Macfarlane R: Neurovascular and molecular mechanisms in migraine headaches. Cerebrovasc Brain Metab Rev 1993, 5:159-177.
31. Blau JN, Dexter SL: The site of pain origin during migraine attacks. Cephalalgia 1981, 1:143-147.
32. Burstein R, Yamamura H, Malick A, Strassman AM: Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. J Neurophysiol 1998, 79:964-982.
33. Blin O, Azulay GP, Masson G, Aubrespy G, Serratrice G: Apomorphine-induced yawning in migraine patients: enhanced responsiveness. Clin Neuropharmacol 1991, 14:91-95.
34. Bes A, Guell A, Victor G, Bru A, Jauzac PH, Geraud G: Effects of a dopaminergic agonist (Piribedil) on CBF in migraine patients. J Cereb Blood Flow Metabol 1981, 1(suppl 1):S549-S550.
35. Fanciullacci M, Michelacci S, Curradi C, Sicuteri F: Hyperresponsiveness of migraine patients to the hypotensive action of bromocriptine. Headache 1980, 20:99-102.
36. Del Zompo M, Lai M, Loi V, Pisano MR: Dopamine hypersensitivity in migraine: role in apomorphine syncope. Headache 1995, 35:222-224.
37. Lance JW: Headache. Ann Neurol 1981, 10:1-10.
38. Wilkinson M: treatment of the acute migraine attack - current status. Cephalalgia 1983, 3:61-67.
39. Callahan M, Raskin N: A controlled study of dihydroergotamine in the treatment of acute migraine headache. Headache 1986, 26:168-171.
40. Krymchantowski AV, Adriano M, Fernandes D: Tolfenamic acid decreases migraine recurrence when used with sumatriptan. Cephalalgia 1999, 19:186-7.
41. Krymchantowski AV: Naproxen sodium decreases migraine recurrence when administered with sumatriptan. Arq Neuropsiquiatr 2000, 58(2-B):428-430.
42. Krymchantowski AV, Barbosa JS: Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open pilot study. Cephalalgia 2002, 22:309-312.